Annovis Bio Stock (NYSE:ANVS)
Previous Close
$4.71
52W Range
$4.40 - $22.49
50D Avg
$7.50
200D Avg
$8.54
Market Cap
$62.02M
Avg Vol (3M)
$276.60K
Beta
1.70
Div Yield
-
ANVS Company Profile
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| AVXL | Anavex Life Sciences Corp. |
| IOVA | Iovance Biotherapeutics, Inc. |
| LTRN | Lantern Pharma Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| TFFP | TFF Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| IMNM | Immunome, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| AXSM | Axsome Therapeutics, Inc. |
| SAVA | Cassava Sciences, Inc. |
| NVAX | Novavax, Inc. |
| ANIX | Anixa Biosciences, Inc. |